This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

YS110

Y's Therapeutics, Inc.

Drug Names(s): YS-110, YSCMA

Description: YS110 is a humanized anti-CD26 monoclonal antibody.

Deal Structure: Y's Therapeutics and Kissei
In September 2009, Y's Therapeutics and Kissei announced an exclusive licensing agreement in Japan to develop and commercialize YSCMA, a humanized anti-CD26 monoclonal antibody. Under the terms of this agreement, Kissei will develop and commercialize YSCMA for the treatment of malignant mesothelioma in Japan.

Partners: Kissei Pharmaceutical Co., Ltd


YS110 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug